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E-mail address: njs@le.ac.uk (N.J. Samani).Myocyte stress 1 (MS1) is a recently described striated muscle actin-binding protein that is up-reg-
ulated in the early stages of pressure overload left ventricular hypertrophy. The aim of this study
was to determine whether MS1 induces cellular hypertrophy and protects against apoptosis.
Over-expressed MS1 co-localized with actin in H9c2 cells and altered expression of genes of the
myocardin-related transcription factor (MRTF)/serum response factor (SRF) transcriptional path-
ways and in addition the apoptosis repressor with caspase recruitment domain (Nol3) gene. The size
of cells over-expressing MS1 was signiﬁcantly increased by 55% and over-expression of MS1 dramat-
ically inhibited staurosporine-induced apoptosis by 89%. These ﬁndings suggest the involvement of
MS1 in cellular hypertrophy and protection against apoptosis.
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Left ventricular hypertrophy (LVH) is an adaptation of the heart
in response to an increased workload, stress or injury [1]. Initially
this adaptation of the heart is beneﬁcial but sustained cardiac
hypertrophy is associated with decompensation and heart failure,
partly due to cell death caused by apoptosis [2]. Many signaling
pathways have been shown to regulate hypertrophy but the
molecular controllers that sense pressure overload and initiate
hypertrophy are unclear. To better understand the initial molecular
mechanisms that lead to pressure-induced LVH, we have identiﬁed
and characterized a novel gene, designated myocyte stress 1 [MS1;
also known as STARS (striated muscle activator of Rho signaling)on behalf of the Federation of Euro
S1, myocyte stress 1; STARS,
actin-binding Rho activating
-related transcription factor;
iocyanate; BSA, bovine serum
ruitment domain; LIF, leuke-
elated antigen-1; BNP, brain
ardiovascular Sciences, Uni-
eneral Hospital, Groby Road,and ABRA (actin-binding Rho activating protein)], which is up-reg-
ulated within 1-h in the left ventricle following aortic banding in
the rat with a peak expression well before any detectable increase
in LV mass [3,4]. This suggests a possible role for MS1 in the initial
signaling of the hypertrophic response. Ms1 is also expressed dur-
ing embryonic cardiac development, is restricted to striated muscle
and is transiently up-regulated during ischemia-reperfusion
in vitro [4,5], which suggests that MS1 may play a more wide-
spread role in cardiac development and physiology.
The mouse homolog of ms1 termed STARS was shown to be a
sarcomeric actin-binding protein which stimulates serum response
factor (SRF)-dependent transcription by inducing the nuclear accu-
mulation of the SRF co-factors, myocardin-related transcription
factors (MRTFs) MRTF-A and MRTF-B through a mechanism depen-
dent on RhoA and actin polymerization [5,6]. Experiments using a
cell line that expresses dominant negative MRTF-A identiﬁed genes
that were MRTF-dependent where some were known SRF target
genes [7]. Many of the MRTF-dependent genes have been associ-
ated with cardiac hypertrophy [8,9] and cell survival [10,11];
therefore, it is conceivable that these MRTF-dependent genes are
putative targets of MS1. Here, we have investigated the role of
MS1 in cellular hypertrophy and survival and report that MS1
over-expression increases cell size and protects against apoptosis
in vitro.pean Biochemical Societies.
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2.1. Cell size and cell proliferation measurements
Following transfection for 72 h, H9c2 cells were trypsinized,
washed with phosphate-buffered saline (PBS) and then cells were
re-suspended in 1 mL PBSA (PBS containing 0.03% (w/v) sodium
azide and 0.2% (w/v) bovine serum albumin (BSA)). Viable cells
were counted and adjusted to 1  105 cells/100 ll PBSA. Cells
were then ﬁxed and permeabilized using a Leucoperm kit (Sero-
tec). During permeabilization mouse anti c-Myc ﬂuorescein isothi-
ocyanate (FITC) antibody (Serotec) was added at 1:10 dilution in
PBS and left for 30 min at room temperature in the dark. The c-
Myc FITC ﬂuorescence of individual transfected cells and the size
of cells (forward scatter) were measured using a Beckman Coulter
Epics XLMCL ﬂow cytometer and System II software.
Cell proliferation was examined 72 h after transfection by direct
cell counting and ﬂow cytometry (see Supplementary data for
details).
2.2. Measurement of apoptosis (DNA fragmentation)
Initial studies looked at the effects of staurosporine on H9c2
cells. Cells were treated with various concentrations of stauro-
sporine (5–25 nM) for 24 h and stained with Vybrant DyeCycle
Violet Stain (Invitrogen) according to the manufacturer’s protocol.
The percentage of apoptotic cells (sub-G1) were measured using a
DakoCytomation CyAn ADP ﬂow cytometer and analyzed using the
Summit v4.3 software.
Following transfection for 24 h, H9c2 cells were treated with
5 nM staurosporine (Sigma) for 24 h. Cells were then collected, la-
beled with mouse anti c-Myc FITC antibody to detect transfected
cells and stained with the Vybrant DyeCycle Violet stain (Invitro-
gen) according to the manufacturer’s protocol.
Methods for Myc-MS1 expression plasmid, Cell culture and
transfection, Immunoﬂuorescence microscopy, real-time and
semi-quantitative RT-PCR, and Western blotting, see Supplemen-
tary data for details.Fig. 1. Changes in gene expression following myocyte stress 1 (MS1) over-expression
transfection for 24 h except for brain natriuretic peptide (BNP) and cardiac a-actin which
normalized to an internal control and the fold change in abundance is presented relative t
for BNP, cardiac a-actin and NOL3 (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 versus empty2.3. Statistical analysis
Differences between sets of data were compared using Stu-
dent’s t-test. A P-value < 0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. Altered expression of hypertrophic and cell survival genes in H9c2
cells over-expressing MS1
The MS1 expression vector over-expressed ms1 mRNA and MS1
protein in H9c2 cells and in cells over-expressing MS1 the MS1 sig-
nal co-localized with actin (see Supplementary data for details).
Over-expression of MS1 signiﬁcantly induced the known MRTF-
dependent genes leukemia inhibitory factor (LIF) and interleukin-6
(IL-6) and the known MRTF-SRF target genes adrenomedullin, jun-
B, and fra-1 (Fig. 1). LIF and IL-6 were up-regulated by 2.5-fold
(P < 0.01) and 5.9-fold (P < 0.001), respectively. A signiﬁcant
induction of 1.6-fold was observed for adrenomedullin (P < 0.05).
Jun-B and fra-1 were increased 2.3-fold (P < 0.01) and 2.1-fold
(P < 0.01), respectively. In addition, genes that have been associ-
ated with cardiac hypertrophy such as cardiac a-actin and BNP
were also up-regulated in H9c2 cells over-expressing MS1 by
2.3-fold (P < 0.01) and 4.5-fold (P < 0.01), respectively (Fig. 1).
It is well established that apoptosis accounts for cardiac cell
death during ischemia/reoxygenation, hypertension, and in mal-
adaptive hypertrophy [12], disease states which induces cardiac
ms1 expression. The BCL-2 family proteins play a central role in
regulating apoptosis in the heart [2,13], therefore we measured
the expression of two pro-survival factors (Bcl-2 and Bcl-xL) in
H9c2 cells over-expressed with MS1 but found no change in their
mRNA expression (data not shown). Another factor of interest is
Nol3 (Apoptosis repressor with caspase recruitment domain), an
apoptosis repressor gene expressed predominantly in striated
muscle [14] and has been shown to inhibit staurosporine-induced
apoptosis [15]. Over-expression of MS1 increased Nol3 mRNA
abundance in H9c2 cells by 2.2-fold (P < 0.05).. Transcript levels for each gene were quantiﬁed by real-time RT-PCR following
were measured by semi-quantitative RT-PCR 72 h after transfection. Each gene was
o empty vector control. Bars showmean ± S.E.M from 6 separate experiments except
vector control.
Fig. 2. Over-expression of MS1 in vitro results in cellular hypertrophy. H9c2 cells
were transfected with a Myc-MS1 expression plasmid or empty vector control and
stained with c-Myc FITC antibody to detect transfected cells. The median cell size
(forward angle light scatter) expressed in arbitrary units of MS1 transfected cells
versus empty vector transfected cells and untransfected cells (cells that remained
untransfected following transfection of the Myc-MS1 expression plasmid) were
quantiﬁed by ﬂow cytometry. Bars show mean ± S.D. from 4 separate experiments.
*P < 0.01.
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Within the population of cells transfected with the Myc-MS1
expression plasmid, on average 13.1 ± 0.5% of cells over-expressed
MS1. In each experiment 10 000 cells were analysed by ﬂow cytom-
etry and therefore 1300 quantiﬁed cells over-expressed MS1. The
size of cells over-expressing MS1 was signiﬁcantly increased by
46.6 ± 6.7% (P < 0.01) when compared to the untransfected portion
of cells (Fig. 2). Similarly, they were signiﬁcantly larger by
54.5 ± 8.5% (P < 0.01) then cells exposed to empty vector control.
Neither the transfection procedure nor the over-expression of
MS1 affected cell proliferation. This was measured by direct cell
counting and ﬂow cytometry, which showed no difference in the
proportion of cells over-expressing MS1 in either S phase or the
G2/M phase of the cell cycle when compared to the untransfectedFig. 3. MS1 over-expression inhibits apoptosis induced by staurosporine in H9c2 cells.
vector control and left untreated or treated with 5 nM staurosporine for 24 h, stained wi
apoptotic cells (sub-G1 phase), respectively, by ﬂow cytometry. Shown are the percenta
untransfected portion of cells exposed to the Myc-MS1 plasmid. The results are the meportion of cells or cells exposed to empty vector control (data
not shown).
3.3. MS1-over-expression in vitro protects against staurosporine-
induced apoptotic cell death
Within the population of cells exposed to the Myc-MS1 expres-
sion plasmid, 1.6 ± 0.5% of the untransfected portion of cells
showed evidence of apoptosis under basal conditions. This propor-
tion was similar (2.1 ± 0.7%) in cells exposed to empty vector. How-
ever, in MS1 expressing cells, the proportion of apoptotic cells was
signiﬁcantly lower (0.7 ± 0.3%) compared to the untransfected por-
tion of cells or cells exposed to empty vector (P < 0.05) (Fig. 3).
Treatment with a sub-maximal concentration of 5 nM stauro-
sporine for 24 h (Supplementary data) markedly increased the per-
centage of apoptotic untransfected portion of cells exposed to the
Myc-MS1 plasmid to 29.0 ± 2.9% (P < 0.001 compared with basal
level). This level of increase was similar in cells exposed to empty
vector (32.4 ± 3.8%, P = 0.23). However, in MS1 transfected cells,
while there was a signiﬁcant increase in apoptotic cells after
5 nM staurosporine for 24 h (3.5 ± 1.0%, P < 0.05 compared with ba-
sal level), the increase was markedly attenuated (P < 0.001) com-
pared with the empty vector exposed cells or the untransfected
cells. The attenuation in apoptosis compared with the empty vec-
tor exposed cells was 89%. These results suggest that MS1 over-
expression affects basal apoptosis and largely prevents stauro-
sporine-induced apoptotic cell death.
4. Discussion
Previous studies have shown that cardiacms1 is over-expressed
during the development of LVH in experimental animal models
[4,16]. More recently, ms1 expression has also been shown to par-
allel the development and regression of skeletal muscle hypertro-
phy in humans [17]. Consistent with these observations, our
present in vitro ﬁnding that increased MS1 levels results in an in-
crease in cell size, provides further evidence of its role in striated
muscle hypertrophy. Interestingly, we found no evidence that in-
creased MS1 levels affected cell proliferation suggesting that its ef-
fects are restricted to causing hypertrophy rather than hyperplasia.
Here, we conﬁrmed that MS1 associates with the actin cytoskel-
eton and causes the over-expression of hypertrophic and cardio-H9c2 cells were transfected (24 h) with a Myc-MS1 expression plasmid or empty
th c-Myc FITC antibody and Vybrant DyeCycle Violet Stain to detect transfected and
ge of apoptotic MS1 transfected cells versus empty vector transfected cells and the
an ± S.D. from 4 independent experiments. *P < 0.05, **P < 0.001.
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[7]. The structural gene cardiac a-actin has also been identiﬁed as
MRTF-dependent [18]. Four (cardiac a-actin, jun-B, fos-related
antigen-1 (fra-1) and adrenomedullin) out of these six MRTF-
dependent genes contains one or more conserved SRF binding sites
which have been experimentally validated as SRF target genes
[7,19–23], suggesting that MS1 causes the over-expression of sev-
eral genes of the MRTF/SRF signaling pathways. In addition, MS1
increased the expression of the hypertrophic marker brain natri-
uretic peptide (BNP), which is known to be a direct target of SRF
[24]. Of particular interest, ms1 itself has a conserved SRF binding
site, which can be bound by SRF in vivo (Ounzain and Chong,
unpublished), raising the possibility that ms1 is a SRF target, thus
creating a previously unrecognised feed-forward mechanism.
Perhaps our most notable ﬁnding is the demonstration that MS1
markedly attenuated staurosporine-induced apoptosis of H9c2
cells. The speciﬁc mechanism whereby MS1 protects against
staurosporine-induced apoptosis remains to be elucidated but it
may involve the expression of Bcl family and related genes
[14,15,25]. Speciﬁcally we have shown that MS1 up-regulated
Nol3, a known cardioprotective gene [14,25–27]. Interestingly,
apoptosis repressor with caspase recruitment domain (NOL3) has
been shown to inhibit staurosporine-induced apoptosis [15] there-
fore, it is reasonable to suggest that MS1 may prevent stauro-
sporine-induced apoptosis via NOL3.
The technique we employed for assessing the effect of transient
MS1 over-expression on apoptosis has been widely used and vali-
dated against other assays of apoptosis [28–30]. Also, we observed
a marked protective effect of MS1 against staurosporine-induced
apoptosis making it highly likely that the effect is genuine. None-
theless, further studies using different assays are necessary to con-
ﬁrm the current ﬁndings.
In summary, we have demonstrated for the ﬁrst time the
involvement of MS1 in cellular hypertrophy and protection
possibly via a MRTF/SRF and/or NOL3 signaling mechanism.
Although these ﬁndings require conﬁrmation in vivo, results
presented here provide support that MS1 plays a central role in
the MRTF/SRF signaling pathway, with important cellular conse-
quences. Collectively, these ﬁndings support further studies to
explore the beneﬁcial effects of the MS1-MRTF-SRF and NOL3
pathway as a therapeutic target for the treatment of cardiovascu-
lar disease.
Acknowledgements
We thank Samir Ounzain for helpful discussions. A.L.K. was sup-
ported by a Thomas Herbert Wathes Centenary Scholarship Grant.
N.J.S. holds a British Heart Foundation Chair of Cardiology.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2009.08.011.
References
[1] Kannel, W.B. (1983) Prevalence and natural history of electrocardiographic left
ventricular hypertrophy. Am. J. Med. 75, 4–11.
[2] Dorn, G.W. (2009) Apoptotic and non-apoptotic programmed cardiomyocyte
death in ventricular remodelling. Cardiovasc. Res. 81, 465–473.
[3] Mahadeva, H., Starkey, M.P., Sheikh, F.N., Mundy, C.R. and Samani, N.J. (1998) A
simple and efﬁcient method for the isolation of differentially expressed genes.
J. Mol. Biol. 284, 1391–1398.
[4] Mahadeva, H., Brooks, G., Lodwick, D., Chong, N.W. and Samani, N.J. (2002)
Ms1, a novel stress-responsive, muscle-speciﬁc gene that is up-regulated in
the early stages of pressure overload-induced left ventricular hypertrophy.
FEBS Lett. 521, 100–104.[5] Arai, A., Spencer, J.A. and Olson, E.N. (2002) STARS, a striated muscle activator
of Rho signaling and serum response factor-dependent transcription. J. Biol.
Chem. 277, 24453–24459.
[6] Kuwahara, K., Barrientos, T., Pipes, G.C., Li, S. and Olson, E.N. (2005) Muscle-
speciﬁc signaling mechanism that links actin dynamics to serum response
factor. Mol. Cell Biol. 25, 3173–3181.
[7] Selvaraj, A. and Prywes, R. (2004) Expression proﬁling of serum inducible
genes identiﬁes a subset of SRF target genes that are MKL dependent. BMC
Mol. Biol. 5, 13.
[8] Kodama, H., Fukuda, K., Pan, J., Makino, S., Baba, A., Hori, S. and Ogawa, S.
(1997) Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine,
activates the JAK/STAT pathway in rat cardiomyocytes. Circ. Res. 81, 656–663.
[9] Fredj, S., Bescond, J., Louault, C., Delwail, A., Lecron, J.C. and Potreau, D. (2005)
Role of interleukin-6 in cardiomyocyte/cardiac ﬁbroblast interactions during
myocyte hypertrophy and ﬁbroblast proliferation. J. Cell Physiol. 204, 428–
436.
[10] Okumura, H., Nagaya, N., Itoh, T., Okano, I., Hino, J., Mori, K., Tsukamoto, Y.,
Ishibashi-Ueda, H., Miwa, S., Tambara, K., Toyokuni, S., Yutani, C. and Kangawa,
K. (2004) Adrenomedullin infusion attenuates myocardial ischemia/
reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent
pathway. Circulation 109, 242–248.
[11] Matsushita, K., Iwanaga, S., Oda, T., Kimura, K., Shimada, M., Sano, M.,
Umezawa, A., Hata, J. and Ogawa, S. (2005) Interleukin-6/soluble interleukin-6
receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab.
Invest. 85, 1210–1223.
[12] Lee, Y. and Gustafsson, A.B. (2009) Role of apoptosis in cardiovascular disease.
Apoptosis 14, 536–548.
[13] Gustafsson, A.B. and Gottlieb, R.A. (2007) Bcl-2 family members and apoptosis,
taken to heart. Am. J. Physiol. Cell Physiol. 292, C45–C51.
[14] Koseki, T., Inohara, N., Chen, S. and Nunez, G. (1998) ARC, an inhibitor of
apoptosis expressed in skeletal muscle and heart that interacts selectively
with caspases. Proc. Natl. Acad. Sci. USA 95, 5156–5160.
[15] Ekhterae, D., Platoshyn, O., Zhang, S., Remillard, C.V. and Yuan, J.X. (2003)
Apoptosis repressor with caspase domain inhibits cardiomyocyte apoptosis by
reducing K+ currents. Am. J. Physiol. Cell Physiol. 284, C1405–C1410.
[16] Kuwahara, K., Pipes, G.C., McAnally, J., Richardson, J.A., Hill, J.A., Bassel-Duby,
R. and Olson, E.N. (2007) Modulation of adverse cardiac remodeling by STARS,
a mediator of MEF2 signaling and SRF activity. J. Clin. Invest. 117, 1324–1334.
[17] Lamon, S., Wallace, M.A., Leger, B. and Russell, A.P. (2009) Regulation of STARS
and its downstream targets suggest a novel pathway involved in human
skeletal muscle hypertrophy and atrophy. J. Physiol. 587, 1795–1803.
[18] Cen, B., Selvaraj, A., Burgess, R.C., Hitzler, J.K., Ma, Z., Morris, S.W. and Prywes,
R. (2003) Megakaryoblastic leukemia 1, a potent transcriptional coactivator
for serum response factor (SRF), is required for serum induction of SRF target
genes. Mol. Cell Biol. 23, 6597–6608.
[19] Minty, A. and Kedes, L. (1986) Upstream regions of the human cardiac actin
gene that modulate its transcription in muscle cells: Presence of an
evolutionarily conserved repeated motif. Mol. Cell Biol. 6, 2125–2136.
[20] Miwa, T. and Kedes, L. (1987) Duplicated CArG box domains have positive and
mutually dependent regulatory roles in expression of the human alpha-
cardiac actin gene. Mol. Cell Biol. 7, 2803–2813.
[21] Miano, J.M. (2003) Serum response factor: Toggling between disparate
programs of gene expression. J. Mol. Cell Cardiol. 35, 577–593.
[22] Adiseshaiah, P., Peddakama, S., Zhang, Q., Kalvakolanu, D.V. and Reddy, S.P.
(2005) Mitogen regulated induction of FRA-1 proto-oncogene is controlled by
the transcription factors binding to both serum and TPA response elements.
Oncogene 24, 4193–4205.
[23] Sun, Q., Chen, G., Streb, J.W., Long, X., Yang, Y., Stoeckert Jr., C.J. and Miano, J.M.
(2006) Deﬁning the mammalian CArGome. Genome Res. 16, 197–207.
[24] Nelson, T.J., Balza Jr., R., Xiao, Q. and Misra, R.P. (2005) SRF-dependent gene
expression in isolated cardiomyocytes: Regulation of genes involved in cardiac
hypertrophy. J. Mol. Cell Cardiol. 39, 479–489.
[25] Ekhterae, D., Lin, Z., Lundberg, M.S., Crow, M.T., Brosius III, F.C. and Nunez, G.
(1999) ARC inhibits cytochrome c release from mitochondria and protects
against hypoxia-induced apoptosis in heart-derived H9c2 cells. Circ. Res. 85,
e70–e77.
[26] Neuss, M., Monticone, R., Lundberg, M.S., Chesley, A.T., Fleck, E. and Crow, M.T.
(2001) The apoptotic regulatory protein ARC (apoptosis repressor with
caspase recruitment domain) prevents oxidant stress-mediated cell death by
preserving mitochondrial function. J. Biol. Chem. 276, 33915–33922.
[27] Gustafsson, A.B., Sayen, M.R., Williams, S.D., Crow, M.T. and Gottlieb, R.A.
(2002) TAT protein transduction into isolated perfused hearts: TAT-apoptosis
repressor with caspase recruitment domain is cardioprotective. Circulation
106, 735–739.
[28] Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F. and Riccardi, C. (1991) A
rapid and simple method for measuring thymocyte apoptosis by propidium
iodide staining and ﬂow cytometry. J. Immunol. Methods 139, 271–279.
[29] Telford, W.G., King, L.E. and Fraker, P.J. (1991) Evaluation of glucocorticoid-
induced DNA fragmentation in mouse thymocytes by ﬂow cytometry. Cell
Proliferation 24, 447–459.
[30] Telford, W.G., King, L.E. and Fraker, P.J. (1992) Comparative evaluation of
several DNA binding dyes in the detection of apoptosis-associated chromatin
degradation by ﬂow cytometry. Cytometry 13, 137–143.
